心肌纤维化和心力衰竭中与亡相关的非编码RNA:对病原和治疗的影响
Hao Wu1,2, Lei Xia1,2, Chunli Liu1,2
1Shandong Public Health Clinical Center, Jinan, 250100, People's Republic of China.
Journal of inflammation research
|August 27, 2025
概括
失调的非编码RNAs (ncRNAs) 驱动心肌细胞亡,导致心力衰竭和心脏纤维化. 对这些心血管疾病来说,抑制前性微RNAs (miRNAs) 是一个有前途的治疗策略.
科学领域:
- 心血管生物学
- 分子遗传学
- 细胞生物学
背景情况:
- 心脏衰竭和心肌纤维化是全球主要的健康负担.
- 亡是HF和心脏纤维化进展的一个关键机制.
- 非编码RNAs (ncRNAs) 调节基因表达和亡;它们的失调有助于心血管疾病 (CVD).
研究的目的:
- 研究ncRNA失调在心肌细胞亡中的作用.
- 探索针对HF和心脏纤维化的促细胞衰退的微RNA (miRNA) 的治疗策略.
主要方法:
- 对ncRNAs,细胞亡和心血管疾病的当前文献的综述.
- 将ncRNA失调与心肌细胞亡联系起来的机制的分析.
- 针对miRNA的治疗方法的评估.
主要成果:
- ncRNA失调与过度的心肌细胞亡有关.
- 在HF和心脏纤维化的发病过程中,亲断性miRNAs起着至关重要的作用.
- 对特定miRNA的治疗抑制显示出治疗这些疾病的潜力.
结论:
- 针对ncRNAs,特别是亲细胞断裂的miRNAs,是治疗HF和心肌纤维化的一个有希望的途径.
- 像干细胞衍生外体和草药等策略可能通过调节miRNA活动来提供新的治疗方法.
更多相关视频
相关概念视频
Pathophysiology of Heart Failure
1.8K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.8K
Heart Failure II: Pathophysiology
38
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
38
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
505
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
505
Heart Failure I: Introduction
54
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
54
Cardiomyopathy I: Introduction and Classification
51
Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
51
Cardiomyopathy IV: Restrictive Cardiomyopathy
28
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
28


